Education
About Us
Working with TipRanks
Follow Us
Kyverna Therapeutics, Inc. (KYTX)
NASDAQ:KYTX
KYTX Stock Chart & Stats
$7.67
-$0.14(-3.63%)
At close: 4:00 PM EST
$7.67
-$0.14(-3.63%)
Day’s Range― - ―
52-Week Range$1.78 - $8.45
Previous CloseN/A
Volume87.17K
Average Volume (3M)705.16K
Market Cap
$275.04M
Enterprise Value-$73.06M
Total Cash (Recent Filing)$171.14M
Total Debt (Recent Filing)$5.02M
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Apr 01, 2026EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding43,245,667
10 Day Avg. Volume1,153,945
30 Day Avg. Volume705,161
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.54
Price to Sales (P/S)0.00
P/FCF Ratio-1.23
Enterprise Value/Market Cap-0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit36.64
Enterprise Value/Ebitda0.46
Forecast
1Y Price Target
$23.67Price Target Upside208.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe upcoming readout from the pivotal trial of KYV-101 in stiff person syndrome (SPS) and subsequent BLA filling are viewed as de-risked near-term catalysts for the stock.
Financial PositionKyverna had cash, cash equivalents, and restricted cash of $171.1 million, which should be sufficient to fund operations into 2027.
Regulatory ProgressKyverna is continuing to execute on its fast-to-market strategy for KYV-101 in neuroinflammatory diseases and is poised to have the first FDA-approved CAR-T for the treatment of an autoimmune disease.
Bears Say
Safety ConcernsThere were three cases of grade 3/4 neutropenia that were associated with lymphodepletion, two of which were transient and resolved within 10 days.
Kyverna Therapeutics, Inc. News
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $1.78 and its highest was $8.45 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Kyverna Therapeutics, Inc.’s market cap is $275.04M.
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is Apr 01, 2026 which is in 122 days.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on Nov 12, 2025. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$0.971 by $0.121.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate is -0.89.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 43,245,667 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$0.85 in its last earnings report, beating expectations of -$0.971. Following the earnings report the stock price went down -11.596%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYTX
Kyverna Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.67 (208.60% Upside)
$23.67 (208.60% Upside)
Hedge Fund Trend
Increased
By 252.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 14.1%
Last 30 Days ▲ 14.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.34%
12-Months-Change
Fundamentals
Return on Equity
-70.82%
Trailing 12-Months
Asset Growth
-37.62%
Trailing 12-Months
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. (KYTX) is a biotechnology company focused on developing innovative cell therapies for the treatment of autoimmune diseases. The company aims to harness advanced technologies in cell engineering and immunology to provide durable and transformative solutions for patients. Kyverna's core products are centered around its proprietary KYV-101 platform, which is designed to modulate the immune system and offer new treatment options for conditions such as lupus and rheumatoid arthritis.
KYTX Stock 12 Month Forecast
Average Price Target
$23.67
▲(208.60% Upside)
Technical Analysis
Codexis
―
Heron Therapeutics
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
21.07% Insiders
7.59% Mutual Funds
35.37% Other Institutional Investors
32.43% Public Companies and Individual Investors